Outstanding MRI contrast with dysprosium phosphate nanoparticles of tuneable size-Reference-Cited by-同舟云学术

Outstanding MRI contrast with dysprosium phosphate nanoparticles of tuneable size

Published:2022 Issue:31 Volume:14 Page:11461-11470
ISSN:2040-3364
Container-title:Nanoscale
language:en
Short-container-title:Nanoscale

Author:

Gómez-González Elisabet¹^ORCID,Caro Carlos²^ORCID,García-Martín María L.²^ORCID,Becerro Ana Isabel¹^ORCID,Ocaña Manuel¹^ORCID

Affiliation:

1. Instituto de Ciencia de Materiales de Sevilla (ICMS) CSIC-Universidad de Sevilla, c/Américo Vespucio, 49, 41092 Seville, Spain

2. Instituto de Investigación Biomédica de Málaga – Plataforma Bionand (IBIMA-Plataforma BIONAND) and CIBER-BBN, Málaga 29590, Spain

Abstract

A series of DyPO4 nanoparticles with tunable size was synthesized and their magnetic relaxivity was analyzed to study their application as high-field MRI contrast agents.

Funder

Junta de Andalucía

Agencia Estatal de Investigación

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science

Link

http://pubs.rsc.org/en/content/articlepdf/2022/NR/D2NR02630A

Reference40 articles.

1. The future of ultra-high field MRI and fMRI for study of the human brain

2. Highly brain-permeable apoferritin nanocage with high dysprosium loading capacity as a new T2 contrast agent for ultra-high field magnetic resonance imaging

3. 9.4T human MRI: Preliminary results

4. Multimodal neuroimaging in humans at 9.4 T: a technological breakthrough towards an advanced metabolic imaging scanner

5. Effects of 3.5–23.0 T static magnetic fields on mice: A safety study

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the Biomedical Potential of PLA/Dysprosium Phosphate Composites via Extrusion-Based 3D Printing: Design, Morphological, Mechanical, and Multimodal Imaging and Finite Element Modeling;ACS Applied Bio Materials;2023-11-10

2. Magnetic Nanoparticle-Based High-Performance Positive and Negative Magnetic Resonance Imaging Contrast Agents;Pharmaceutics;2023-06-15